Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Slovenia

Innovation Action · Running

SHIELD Comprehensive Surveillance of High-risk Individuals and Health Integration for Early detection of Pancreatic cancer utilising innovative multiplex immunoassays

Coordinator
Univerzitetni klinicni center Maribor, Slovenia
Runs
1 May 2025 to 30 April 2029
Status
Running
EU funding
€11.6m
Total cost
€14.1m
Partners
27 organisations in 13 countries
Type
Innovation Action
Grant agreement
101214779

What the project is doing

In the project's own words, from its summary on CORDIS.

The SHIELD project seeks to revolutionise early detection of pancreatic cancer, focusing on individuals with high heritable genetic risk. Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival rate of less than 10%, primarily due to late-stage diagnosis. Consequently, 85% of PDAC cases are identified too late for curative treatment. However, early detection can significantly improve outcomes, increasing the survival rate to 42% with surgical intervention.

There is a pressing need for better early detection methods, especially for those with familial or genetic predispositions. The only FDA-approved biomarker, CA19-9, is limited to monitoring treatment response due to its lack of sensitivity and specificity, while imaging methods ofter fail to detect early-stage cancers and cause a strain to the healthcare system due to their cost and limited availability. SHIELD aims to validate a new blood-based diagnostic test designed for early PDAC detection in high-risk individuals and pilot an early detection programme in Greece, Slovenia and Lithuania.

Developed by partner Reccan, this test uses a 5-plex multiple immunoassay to analyze protein readouts and provides a probability score for pancreatic cancer. Initial studies with over 450 samples showed excellent performance with >91% sensitivity and >96% specificity. The project will validate the test's clinical performance in a prospective multi-center study across seven EU countries, targeting individuals with familial or genetic predispositions.

It will also identify new protein biomarkers for other high-risk indications, such as new-onset diabetes (NOD). Collaboration with national screening authorities will help integrate this test into existing programs, and partnerships with patient organizations will enhance recruitment. SHIELD envisions transforming pancreatic cancer diagnostics by increasing the 5-year survival rate to 30% by 2035 in Europe. This action is part of the Cancer Mission cluster of projects on “Prevention & early detection (early detection heritable cancers)

Topics

Who is involved

OrganisationCityCountryRole
Univerzitetni klinicni center MariborMariborSloveniaCoordinator
Centre Hospitalier Universitaire De LiegeLiegeBelgiumParticipant
Digital for Planet-D4pDubendorfSwitzerlandAssociatedpartner
Erevnitiko Idrima P.l.NicosiaCyprusParticipant
Kypriako Idryma Erevnon Gia Ti Myiki DistrofiaAgios DometiosCyprusParticipant
Lackner AnnaLimassolCyprusParticipant
Infineon Technologies AGNeubibergGermanyParticipant
Region SyddanmarkVejleDenmarkParticipant
Anadelta Technologies IkeAthensGreeceParticipant
Brains Innovative Consulting Services Monoprosopi I.k.e.AthensGreeceParticipant
Charokopeio PanepistimioAthinaGreeceParticipant
Computer Solutions Anonymi Viomichaniki Kai Emporiki Etaireia PliroforikisAthensGreeceParticipant
Elliniki Omospondia Karkinou Ell OkAthinaGreeceParticipant
Erevnitiko Panepistimiako Institouto Systimaton Epikoinonion Kai YpologistonAthinaGreeceParticipant
Ethniko Kai Kapodistriako Panepistimio AthinonAthinaGreeceParticipant
Ilektroniki Diakyvernisi Ygeias kai Koinonikis Asfalisis Monoprosopi Anonymi EtaireiaAthensGreeceParticipant
Protavio Monoprosopi E.p.eGlyfadaGreeceParticipant
Fundacion Investigation Hm HospitalesMadridSpainParticipant
DEXAI - Etica ArtificialeRomaItalyParticipant
Vilniaus UniversitetasVilniusLithuaniaParticipant
Netcompany S.a.LuxembourgLuxembourgParticipant
Cancerföreningen PALEMALidingöSwedenParticipant
Lunds UniversitetLundSwedenParticipant
Reccan ABLundSwedenParticipant
Truly Labs ABLundSwedenParticipant
Dita, Razvoj in Storitve, D.o.o.MariborSloveniaParticipant
Pharmecons Easy Access LtdYorkUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI